Reuters logo
BRIEF-Alnylam and Sanofi Genzyme initiate ATLAS Phase 3 program with investigational RNAi therapeutic fitusiran
2017年7月7日 / 中午11点35分 / 2 个月前

BRIEF-Alnylam and Sanofi Genzyme initiate ATLAS Phase 3 program with investigational RNAi therapeutic fitusiran

July 7 (Reuters) - Alnylam Pharmaceuticals Inc

* Alnylam and Sanofi Genzyme initiate ATLAS phase 3 program with investigational RNAi therapeutic fitusiran

* Says expect top-line data from the ATLAS trials in mid-to-late 2019

* says ATLAS studies are expected to enroll about 250 patients across 3 separate trials conducted around the world

* Says ATLAS to evaluate safety and efficacy of Fitusiran across broad spectrum of patients living with hemophilia Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below